For research use only. Not for therapeutic Use.
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson’s disease[1][2].
Cinpanemab is highly selective for aggregated forms of α-syn with at least an 800-fold higher apparent affinity for fibrillar versus monomeric recombinant α-syn and a strong preference for human PD brain tissue[2].
Cinpanemab (30 mg/kg; i.p.) improves PD-like phenotypes in α-syn PFF inoculation mouse models [2].
| Catalog Number | I042236 |
| CAS Number | 2094516-02-4 |
| Purity | ≥95% |
| Reference | [1]. Lang AE, et, al. Trial of Cinpanemab in Early Parkinson’s Disease. N Engl J Med. 2022 Aug 4;387(5):408-420. [2]. Teng JS, et, al. Immunotherapies for Parkinson’s Disease: Progression of Clinical Development. CNS Neurol Disord Drug Targets. 2021;20(9):802-813. |
